Feuchtwang Ilan
Company insiders · Chief Legal Officer, Secretary · Cytek Biosciences, Inc.
- Reported transaction lines
- 1
- Buy lines
- 0
- Sell lines
- 0
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-111
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| Feuchtwang Ilan Chief Legal Officer, Secretary · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Equity grant or awardFiling detailsSEC transaction code A Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 25745 · Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock. · The RSUs shall vest and settle into common stock over 4 years, with 12/48 of the RSUs vesting on November 18, 2027; 4/48 of the RSUs vesting on March 10, 2028 and each March 10 thereafter; 2/48 of the RSUs vesting on May 18, 2028 and each May 18 thereafter; 3/48 of the RSUs vesting on August 18, 2028 and each August 18 thereafter, and 3/48 of the RSUs vesting on November 18, 2028 and each November 18 thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan (the "2021 Plan"))). | 2026-11-09 | 2026-11-12 | 25,745 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.